Discover the differences
Providing more than just results
Therapeutics testing covers a wide-range of areas from controlled substance monitoring to pharmacogenomics (PGx). We provide access to Mayo Clinic experts and a test menu developed through evidence-driven clinical innovation to help clinicians guide patient care.
Discover how the smallest differences can have the greatest impact. Let's find the right answers together.
By the numbers
We're dedicated to our patients' health and well-being,
and proud of the outstanding outcomes we achieve.
190+
laboratory tests developed for our specialized therapeutics test menu
50+
years of research in pharmacogenomics
25M
tests performed
annually
24/7
support from Mayo Clinic physicians and scientists
An individualized approach
When PGx is incorporated into clinical practice, drug selection is enhanced with the genetic profile of individual patients, improving the clinician’s ability to avoid adverse drug reactions and maximize therapeutic efficacy.
Differences that matter
We understand that interpreting testing results can be tricky, so we provide health care providers with customized clinical guidance based on testing results.
Access to Mayo Clinic expertise
When you partner with Mayo Clinic Laboratories, you extend your network to include some of the world’s leading genetic experts. Mayo Clinic clinicians, laboratorians, and genetic counselors are available to discuss testing options, interpret results, or help with case review and coordination.
The Latest
Partnering with Mayo Clinic has helped St. Clair Health improve patient care and gain a new competitive advantage in pharmacogenetics.
John Black, M.D., co-director of the Personalized Genomics Lab at Mayo Clinic, joins the "Answers From the Lab" podcast for a discussion with Bobbi Pritt, M.D., about mental health awareness. In this episode, Dr. Black and Dr. Pritt review key takeaways from Mental Health Awareness Month, the role that lab testing plays in mental health, and the robust science behind treatment.
Paul Jannetto, Ph.D., and Loralie Langman, Ph.D., discuss Mayo Clinic Laboratories' unique approach to urine drug testing for addiction rehabilitation. Designed to guide and monitor therapy, the comprehensive profile tests for the most commonly used substances, including alcohol and nicotine, for a complete picture of a patient’s substance use.
In this month's "Hot Topic," Paul Jannetto, Ph.D., identifies how to determine new vs. residual use of marijuana in a patient, and teaches how to calculate the carboxy-tetrahydrocannabinol (carboxy-THC) to creatinine ratio along with a decision ratio by demonstrating its clinical utility via case study.
PACE/State of CA/State of FL - In this month’s “Virtual Lecture,” Victor Karpyak, M.D., Ph.D., discusses the burden of alcohol use disorders (AUD) on society compared to other neuropsychiatric disorders and reviews the progress of biomarker discovery.